Endovascular therapy for cavernous sinus dural arteriovenous fistulas: a single-center retrospective study
- 1Department of Neurosurgery, Xinxiang Central Hospital, Affiliated with Henan Medical University (The Fourth Clinical College)
- 2Department of Neurosurgery, West China Hospital of Sichuan University
Abstract
Objective: To evaluate the clinical efficacy of endovascular therapy for cavernous sinus dural arteriovenous fistulas (CSDAVFs).
Methods: A single-center, retrospective cohort study was conducted involving patients with CSDAVFs who underwent endovascular therapy performed by a single neurointerventionalist at West China Hospital, Sichuan University, between January 2023 and December 2025. Data collected included demographic characteristics, presenting symptoms and neurological signs, baseline and follow-up imaging findings (including digital subtraction angiography), procedural details (e.g., access route, embolic agents, technical success), and clinical outcomes—including angiographic occlusion status, symptom resolution, procedure-related complications, and functional recovery.
Results: Fourteen patients were diagnosed with cavernous sinus dural arteriovenous fistulas (CSDAVFs). Twelve underwent endovascular treatment following definitive diagnosis by digital subtraction angiography (DSA); two declined intervention despite confirmed diagnosis. Thirteen presented with predominant ocular manifestations—such as proptosis, chemosis, and ophthalmoparesis—while one was diagnosed incidentally on cranial MRI performed for headache and dizziness. All 12 patients underwent the procedure successfully: seven underwent arterial-access embolization and five underwent venous-access embolization. Onyx liquid embolic agent was used as the sole embolic material in seven cases; in the remaining five cases, detachable coils were employed as adjunctive agents. Immediate post-procedural DSA demonstrated complete occlusion in nine patients and subtotal occlusion in three. Procedure-related complications occurred in five patients: visual acuity reduction ( n = 2), ipsilateral facial hypoesthesia ( n = 2), and isolated impairment of abduction and downward gaze ( n = 1). Symptomatic improvement was observed in seven patients. At 1-year clinical and imaging follow-up, all 12 treated patients remained under surveillance. Ten exhibited no recurrence; notably, one patient with initial subtotal occlusion achieved complete angiographic occlusion during follow-up. In the remaining two, residual lesions remained stable in size, symptoms improved, and no secondary intervention was required. Among the five patients with procedure-related complications, two developed persistent facial hypoesthesia after intra-arterial embolization; subjective numbness gradually improved but did not fully resolve during follow-up.
Conclusion: Endovascular therapy for craniospinal dural arteriovenous fistula (CSDAVFs) is associated with favorable clinical and angiographic outcomes. Although procedure-related complications occur in a subset of patients, most are transient and resolve spontaneously or improve to partial remission during follow-up. Collectively, these findings support endovascular therapy as a safe and effective treatment modality for CSDAVFs.
Related
- Morphological, clinical, and procedural determinants of embolization outcomes in non-cavernous cerebral dural arteriovenous fistulas: A retrospective study
- Deep Learning-Based Versus Threshold-Based Bone Removal for CT Angiography of Head and Neck Arteriovenous Fistulas: A Retrospective Comparison of Image Quality, Key-Structure Display, and Post-Processing Time
- Endovascular ultrasound-guided endoprosthesis implantation for post-traumatic arteriovenous fistulas: overcoming the limitations of angiographic imaging
- Metachronous dural arteriovenous fistulas in a single patient: a 25-year evolution of three distinct lesions.
- Modifiable Cardiovascular Risk Factors and Hemorrhagic Presentation in Dural Arteriovenous Fistulas: A Systematic Review With Exploratory Quantitative Synthesis
BibTeX
@article{dong2026endovascular,
title = {{Endovascular therapy for cavernous sinus dural arteriovenous fistulas: a single-center retrospective study}},
author = {Jianfeng Dong and Ting Wang and Xiaodong Xie and Sen Lin},
journal = {Frontiers in Neurology},
year = {2026},
month = nov,
doi = {10.3389/fneur.2026.1984148},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1984148/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Endovascular therapy for cavernous sinus dural arteriovenous fistulas: a single-center retrospective study
AU - Jianfeng Dong
AU - Ting Wang
AU - Xiaodong Xie
AU - Sen Lin
PY - 2026
DA - 2026/11/05
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1984148
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1984148/full
AB - Objective: To evaluate the clinical efficacy of endovascular therapy for cavernous sinus dural arteriovenous fistulas (CSDAVFs). Methods: A single-center, retrospective cohort study was conducted involving patients with CSDAVFs who underwent endovascular therapy performed by a single neurointerventionalist at West China Hospital, Sichuan University, between January 2023 and December 2025. Data collected included demographic characteristics, presenting symptoms and neurological signs, baseline and follow-up imaging findings (including digital subtraction angiography), procedural details (e.g., access route, embolic agents, technical success), and clinical outcomes—including angiographic occlusion status, symptom resolution, procedure-related complications, and functional recovery. Results: Fourteen patients were diagnosed with cavernous sinus dural arteriovenous fistulas (CSDAVFs). Twelve underwent endovascular treatment following definitive diagnosis by digital subtraction angiography (DSA); two declined intervention despite confirmed diagnosis. Thirteen presented with predominant ocular manifestations—such as proptosis, chemosis, and ophthalmoparesis—while one was diagnosed incidentally on cranial MRI performed for headache and dizziness. All 12 patients underwent the procedure successfully: seven underwent arterial-access embolization and five underwent venous-access embolization. Onyx liquid embolic agent was used as the sole embolic material in seven cases; in the remaining five cases, detachable coils were employed as adjunctive agents. Immediate post-procedural DSA demonstrated complete occlusion in nine patients and subtotal occlusion in three. Procedure-related complications occurred in five patients: visual acuity reduction ( n = 2), ipsilateral facial hypoesthesia ( n = 2), and isolated impairment of abduction and downward gaze ( n = 1). Symptomatic improvement was observed in seven patients. At 1-year clinical and imaging follow-up, all 12 treated patients remained under surveillance. Ten exhibited no recurrence; notably, one patient with initial subtotal occlusion achieved complete angiographic occlusion during follow-up. In the remaining two, residual lesions remained stable in size, symptoms improved, and no secondary intervention was required. Among the five patients with procedure-related complications, two developed persistent facial hypoesthesia after intra-arterial embolization; subjective numbness gradually improved but did not fully resolve during follow-up. Conclusion: Endovascular therapy for craniospinal dural arteriovenous fistula (CSDAVFs) is associated with favorable clinical and angiographic outcomes. Although procedure-related complications occur in a subset of patients, most are transient and resolve spontaneously or improve to partial remission during follow-up. Collectively, these findings support endovascular therapy as a safe and effective treatment modality for CSDAVFs.
SN - 1664-2295
ER -